Vascular biomarkers and ApoE4 expression in mild cognitive impairment and Alzheimer's disease

Diana C Oviedo1, Hector Lezcano2, Ambar R Perez1,3

  • 1Universidad Católica Santa María La Antigua (USMA), Panamá.

AIMS Neuroscience
|April 29, 2020
PubMed

Insights

Vascular health impacts cognition in older adults. Increased intima-media thickness and carotid stenosis are linked to poorer memory, language, and attention, supporting their use as biomarkers for cognitive decline.

Area of Science:

  • Neurology
  • Gerontology
  • Cardiology

Background:

  • Vascular pathology and apolipoprotein E allele ε4 (ApoE ε4) are known risk factors for Alzheimer's disease progression.
  • Panama faces a growing aging population and high vascular risk, necessitating accessible biomarkers for early detection.

Purpose of the Study:

  • To investigate the association between vascular biomarkers (intima-media thickness, carotid stenosis), ApoE ε4, and cognitive function in older adults.
  • To explore the utility of non-invasive vascular assessments in primary care settings for cognitive health evaluation.

Main Methods:

  • A descriptive, cross-sectional study of 86 participants (healthy, MCI, AD) from the Panama Aging Research Initiative (PARI).
  • Assessments included neuropsychological testing across six cognitive domains, ApoE ε4 genotyping, and Doppler ultrasound of the carotid artery.
  • Multivariable analyses controlled for age, education, and ApoE ε4 expression.

Main Results:

  • Increased intima-media thickness was associated with poorer memory performance.
  • Carotid stenosis correlated with deficits in language, visuospatial abilities, and attention.
  • These associations were independent of age, education, and ApoE ε4 status.

Conclusions:

  • Vascular markers like intima-media thickness and carotid stenosis show significant associations with cognitive function in older adults.
  • These findings support the integration of vascular assessments into routine cognitive evaluations for early detection of impairment.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
687
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
367